S-18986 //CAS:175340-20-2

FOB Reference Price:Get Latest Price
$1.00 - $100.00 / Gram | 1 Gram/Grams (Min. Order)
Shipping:
Support Sea freight
Report Suspicious Activity
Overview
Quick Details
CAS No.:
175340-20-2
Other Names:
S-18986//IDRA-21
MF:
C10H12N2O2S
EINECS No.:
S-18986//IDRA-21
Place of Origin:
Hubei, China
Type:
Pharmaceutical Intermediates, Syntheses Material Intermediates
Purity:
98%
Brand Name:
HHD-PHARM
Model Number:
HHD-PHARM
Application:
nootropics
Appearance:
White powder
color:
white
Supply Ability
Supply Ability:
1 Kilogram/Kilograms per Quarter
Packaging & Delivery
Packaging Details
ON REQUEST
Port
SH
Lead Time :
PROMPT

S-18986//IDRA-21  

 

 

Superlist Name: S-18986

CAS No.: 175340-20-2

Molecular Formula:C10H12N2O2S 

Purity99%

Synonyms:1H-Pyrrolo[2,1-c][1,2,4]benzothiadiazine, 2,3,3a,4-tetrahydro-, 5,5-dioxide, (3aS)-

 

 

S-18986 is an ampakine drug related to cyclothiazide. It has nootropic and neuroprotective effects in animal studies, and induces both production of BDNF and AMPA-mediated release of noradrenaline and acetylcholine in the hippocampus andfrontal cortex of the brain  

 

IDRA-21 is an ampakine drug and a benzothiadiazine derivative. IDRA-21 is a chiral molecule, with (+)-IDRA-21 being the active form.

IDRA-21 shows nootropic effects in animal studies, significantly improving learning and memory. It is around 10-30x more potent than aniracetam in reversing cognitive deficits induced by alpraz or scopolamine, and produces sustained effects lasting for up to three days after a single dose. The mechanism for this action is thought to be through promoting the induction of long-term potentiation between synapses in the brain.

IDRA-21 does not produce neurotoxicity under normal conditions, although it may worsen neuronal damage following global ischemia after stroke or seizures.

In comparison to the benzoylpiperidine derived ampakine drugs, IDRA-21 was more potent than CX-516, but less potent thanCX-546. Newer benzothiadiazide derivatives with greatly increased potency compared to IDRA-21 have been developed, but these have not been researched to the same extent, with the benzoylpiperidine and benzoylpyrrolidine CX- series of drugs being favoured for clinical development, most likely due to more favourable toxicity profiles at high doses.

 

 

 

FOR RESEARCH USE ONLY!